Journal Mobile Options
Table of Contents
Vol. 58, No. 3, 2011
Issue release date: August 2011
Ann Nutr Metab 2011;58:197–202
(DOI:10.1159/000329727)

Effects of Marine Omega-3 Fatty Acids on Serum Systemic and Vascular Inflammation Markers and Oxidative Stress in Hemodialysis Patients

Kooshki A. · Taleban F.A. · Tabibi H. · Hedayati M.
aDepartment of Nutrition & Biochemistry, Sabzevar University of Medical Sciences, Sabzevar, bDepartment of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, and cPrevention and Treatment of Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background and Aims: High concentrations of serum inflammation markers, especially vascular inflammation markers, are an important risk factor for cardiovascular diseases in hemodialysis patients. The present study was designed to investigate the effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients. Methods: Thirty-four hemodialysis patients were randomly assigned to either the marine omega-3 fatty acid or the placebo group. Patients in the omega-3 fatty acid group received 2,080 mg marine omega-3 fatty acids daily for 10 weeks, whereas the placebo group received a corresponding placebo.At baseline and the end of week 10, 5 ml blood was collected after a 12- to 14-hour fast. Results: Mean serum soluble intercellular adhesion molecule type 1 (sICAM-1) decreased significantly in the omega-3 fatty acid group at the end of week 10 compared to baseline (p < 0.05) and this reduction was significant in comparison with the placebo group (p < 0.05). No significant differences were observed between the two groups in mean changes in serum soluble vascular cell adhesion molecule type 1, sE-selectin, sP-selectin, C-reactive protein, interleukin-6, tumor necrosis factor-α, malondialdehyde and total antioxidant capacity. Conclusion: The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases, but it has no effect on serum systemic inflammation markers and oxidative stress in hemodialysis patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Singh AK, Brenner BM: Dialysis in the treatment of renal failure; in Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds): Harrison’s Principles of Internal Medicine, ed 16. New York, McGraw-Hill, 2005, pp 1663–1667.
  2. Jungers P, Nguyen Khoa T, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, Man NK: Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: a multicentric study in the Ile de France district. Nephrol Dial Transplant 1999;14:898–902.
  3. Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(suppl 8):33–38.
  4. Stenvinkel P, Yeun JY: Role of inflammation in malnutrition and atherosclerosis in chronic renal failure; in Kopple JD, Massry SG (eds): Kopple & Massry’s Nutritional Management of Renal Disease, ed 2. Philadelphia, Lippincott, Williams & Wilkins, 2004, pp 199–212.
  5. Rabb H, Calderon E, Bittle PA, Ramirez G: Alterations in soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in hemodialysis patients. Am J Kidney Dis 1996;27:239–243.
  6. Musial K, Zwolinska D, Polak-Jonkisz D, Berny U, Szprynger K, Szczepanska M: Soluble adhesion molecules in children and young adults on chronic hemodialysis. Pediatr Nephrol 2004;19:332–336.

    External Resources

  7. Musial K, Zwolinska D, Berny U, Polak-Jonkisz D, Szprynger K, Szczepanska M: Soluble adhesion molecules in children and young adults with chronic renal failure treated conservatively (abstract). Rocz Akad Med Bialymst 2004;49:209–212.
  8. Musial K, Zwolinska D, Polak-Jonkisz D, Berny U, Szprynger K, Szczepanska M: Serum VCAM-1, ICAM-1, and L-selectin levels in children and young adults with chronic renal failure. Pediatr Nephrol 2005;20:52–55.
  9. Bolton CH, Downs LG, Victory JGG, Dwight JF, Tomson CRV, Mackness MI, Pinkney JH: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001;16:1189–1197.
  10. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN: Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients: a pilot study. Nephrol Dial Transplant 2007;22:3561–3567.
  11. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, Ristic D: Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 2007;29:321–329.
  12. Madsen T, Schmidt EB, Christensen JH: The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure. J Ren Nutr 2007;17:258–263.

    External Resources

  13. Fiedler R, Mall M, Wand C, Osten B: Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr 2005;15:253–256.

    External Resources

  14. Sampson MJ, Davies IR, Brown JC, Morgan V, Richardson T, James AJ, Sampson AP, Hughes DA: n-3 polyunsaturated fatty acid supplementation, monocyte adhesion molecule expression and pro-inflammatory mediators in type 2 diabetes mellitus. Diabet Med 2001;18:51–58.
  15. Kang M, Ragan BG, Park JH: Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train 2008;43:215–221.

    External Resources

  16. Daugirdas JT, Stone JCV: Physiologic principles and urea kinetic modeling; in Daugirdas JT, Blake PG, Ing TS (eds): Handbook of Dialysis, ed 3. Philadelphia, Lippincott, Williams & Wilkins, 2001, pp 15–4.
  17. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J: Circulating cell adheshion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336–1342.
  18. Tedgui A: The role of inflammation in atherothrombosis: implications for clinical practice. Vasc Med 2005;10:45–53.

    External Resources

  19. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O: Elevated serum levels of soluble adhesion molecules predict death in predialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000;15:1624–1630.
  20. Hjerkinn EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann I, Sandvik L, Arnesen H: Influence of long term intervention with dietary counseling, long-chain n-3 fatty acid supplements or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. Am J Clin Nutr 2005;81:583–589.
  21. Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, Smith CW, Ballantyne CM: Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998;18:723–731.
  22. Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF, Beilin LJ: Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003;166:85–93.
  23. Lee KW, Blann AD, Lip GY: Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res 2006;118:305–312.
  24. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB: Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 2004;134:1806–1811.
  25. Chen W, Esselman WJ, Jump DB, Busik JV: Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 2005;46:4342–4347.

    External Resources

  26. Jacobs P, Glorieux G, Vanholder R: Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. Nephrol Dial Transplant 2004;19(suppl 5):v41–v45.

    External Resources

  27. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ: Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003;35:772–781.
  28. Vega-López S, Kaul N, Devaraj S, Cai RY, German B, Jialal I: Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism 2004;53:236–240.
  29. Kelley DS, Siegel D, Fedor DM, Adkins Y, Mackey BE: DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 2009;139:495–501.
  30. Moreira AC, Gaspar A, Serra MA, Simões J, Lopes da Cruz J, Amaral TF: Effect of a sardine supplement on C-reactive protein in patients receiving hemodialysis. J Ren Nutr 2007;17:205–213.

    External Resources

  31. Tetta C, Biasiol S, Schiavon R, Inguaggiato P, David S, Panichi V, Wratten ML: An overview of haemodialysis and oxidant stress. Blood Purif 1999;17:118–126.
  32. Canaud B, Cristol JP, Morena M, Leray- Moragues H, Bosc JY, Vaussenat F: Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 1999;17:99–106.
  33. Galli F, Ronco C: Oxidant stress in hemodialysis. Nephron 2000;84:1–5.
  34. Bonanome A, Biasia F, De Luca M, Munaretto G, Biffanti S, Pradella M, Pagnan A: n-3 Fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects. Am J Clin Nutr 1996;63:261–266.
  35. Taccone-Gallucci M, Manca-di-Villahermosa S, Battistini L, Stuffler RG, Tedesco M, Maccarrone M: N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney Int 2006;69:1450–1454.
  36. Ando M, Sanaka T, Nihei H: Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177–2184.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50